Roughly 20% of generalized myasthenia gravis patients carry no detectable AChR antibodies, and until now every major approved therapy left them outside the label. That clinical exclusion ended on May 8, when the FDA approved efgartigimod’s supplemental BLA to cover all adult gMG serotypes — anti-MuSK-Ab positive, anti-LRP4-Ab positive, anti-AChR-Ab positive, and triple seronegative — making VYVGART the only treatment with a serotype-agnostic indication in this disease.
The regulatory action rests on ADAPT SERON, the largest dedicated trial in seronegative and non-AChR gMG to date. The primary endpoint was a statistically significant improvement in MG-ADL total score at week four versus placebo (p=0.0068), with efgartigimod producing a mean 3.35-point change from baseline across the combined non-AChR population. That magnitude matters clinically: a 2-point MG-ADL shift is generally considered the threshold for meaningful functional benefit, so the trial cleared it by a meaningful margin. Crucially, gains in both MG-ADL and QMG scores extended across subsequent treatment cycles, meaning the effect is not a transient IgG-depletion flash but a reproducible, durable signal sustained through repeated dosing.
The design choice to enroll triple seronegative patients is worth underscoring. This subgroup has historically been excluded from registrational studies because their pathogenic mechanism is incompletely characterized and antibody status cannot confirm diagnosis. ADAPT SERON enrolled them anyway, using clinical diagnosis alone as the qualifying criterion. That decision forced a cleaner test of the FcRn-blockade mechanism independent of a measurable antibody target — and the mechanism held. It validates the hypothesis that pathogenic IgG reduction produces functional benefit even when the specific offending autoantibody cannot be identified in serum.
Argenx has also reported positive top-line data from ADAPT OCULUS in ocular MG and is running ADAPT Jr in pediatric gMG, so the label is likely to widen further. But the immediate clinical consequence of today’s action is concrete and operational: neurologists no longer need serotype confirmation before prescribing. The single metric worth tracking now is uptake in newly diagnosed patients who previously would have cycled through immunosuppressants for months while serologic workup remained ambiguous — conversion of that population into early efgartigimod initiators will define whether the broadened label changes real-world treatment sequencing or merely formalizes prescribing that was already happening off-label.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
